Skip to Content

Hologic Inc - Stock Quote HOLX

Rating as of

Morningstar's Hologic Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Hologic Juggles Waning COVID-19 Assay Demand While Setting Up for Long-Term Growth in Second Quarter

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Hologic reported fiscal second-quarter results that featured revenue declining 7% year over year, which was less severe than we’d been expecting thanks to the omicron surge that bolstered demand for COVID-19 assays again. However, we’re holding steady on our fair value estimate, as this quarter’s outperformance on the top line was generally offset by margin erosion thanks to test mix and a resumption in sales and marketing spending. We remain confident in the firm’s narrow economic moat, especially now that it has significantly expanded its installed base of Panther platforms, which sets the stage for an ongoing stream of assay revenue.

Read Full Analysis

Hologic Inc's Company Profile

Business Description

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

250 Campus Drive
Marlborough, MA, 01752
T +1 508 263-2900
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Mar 31, 2022
Fiscal Year End Sep 25, 2022
Stock Type Aggressive Growth
Employees 6,705